---
title: "Ozempic in Special Populations: Transplant, HIV, and More"
description: "Ozempic needs no dose change for kidney or liver impairment. See guidance for transplant recipients, HIV, older adults, MASH data and pregnancy timing."
url: https://healthrx.com/ozempic/special-populations
publisher: HealthRX.com
---


HealthRX.com

No Ozempic dose change for kidney or liver impairment

[Print or save as PDF](https://healthrx.com/printables/ozempic/special-populations?print=1)

From the public record

What the FDA label says about Ozempic in special populations

Use during pregnancy is advised only when the potential benefit justifies the potential risk to the fetus. No dose adjustment is recommended for patients with renal impairment or hepatic impairment, and hepatic impairment does not have any impact on the exposure of semaglutide.

What the FDA label says about Ozempic in special populations: the figures

| Measure | Value | Note |
| --- | --- | --- |
| 8.1 Pregnancy | Pregnancy: use if benefit outweighs risk | "OZEMPIC should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus." |
| 8.6 Renal Impairment | Kidney impairment: no dose change | "No dose adjustment of OZEMPIC is recommended for patients with renal impairment." |
| 8.7 Hepatic Impairment | Liver impairment: no dose change | "No dose adjustment of OZEMPIC is recommended for patients with hepatic impairment." |
| 12.3 Pharmacokinetics | Liver impairment: no effect on exposure | "Patients with Hepatic impairment - Hepatic impairment does not have any impact on the exposure of semaglutide." |

Source: [DailyMed label: Ozempic (semaglutide) injection](https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=adec4fd2-6858-4c99-91d4-531f5f2a2d79), data as of Nov 13, 2026

How this was calculated

Label sentences naming renal impairment, hepatic impairment, pregnancy, geriatric, lactation, quoted word for word under their section names.

Scope: Ozempic (semaglutide) injection label: 4 sentences naming renal impairment, hepatic impairment and pregnancy.

[See the public record for Semaglutide](https://healthrx.com/data/semaglutide)

HealthRX.com quick answer. Ozempic needs no dose adjustment for kidney or liver impairment [1]. The label found no overall safety or efficacy difference in adults 65 and older, though greater sensitivity in some older people cannot be ruled out, and it says to stop Ozempic at least 2 months before a planned pregnancy [1]. In the FLOW trial in type 2 diabetes with chronic kidney disease, there were 331 first kidney or cardiovascular events in the semaglutide group versus 410 on placebo (HR 0.76) [2].

At a glance

- Kidney impairment / No dose adjustment; kidney-outcome indication in type 2 diabetes with CKD
- Liver impairment / No dose adjustment recommended
- MASH / Phase 3 benefit at 2.4 mg weekly, above Ozempic's 2 mg maximum
- Transplant recipients / Label caution on delayed gastric emptying and oral medicines
- HIV / Broken down by proteolysis and beta-oxidation, not CYP enzymes
- Older adults / No overall safety or efficacy difference in the 65-and-over subgroup
- Pregnancy / Label: stop at least 2 months before a planned pregnancy
- Children / Safety and efficacy not established

## Kidney disease: no dose change, and a kidney indication

The Ozempic label recommends no dose adjustment for renal impairment and reports no clinically relevant change in semaglutide exposure in people with renal impairment, including kidney failure [1]. The label's third indication is to reduce the risk of sustained [eGFR](https://healthrx.com/labs-egfr/what-it-measures) decline, end-stage kidney disease and cardiovascular death in adults with type 2 diabetes and [chronic kidney disease](https://healthrx.com/ozempic/renal-impairment) [1]. For that indication the dose runs 0.25 mg weekly for 4 weeks, then 0.5 mg, then 1 mg after at least 4 weeks on 0.5 mg [1].

FLOW is the trial behind that indication. It randomized 3,533 adults with type 2 diabetes and chronic kidney disease to semaglutide 1 mg weekly or placebo, with a median follow-up of 3.4 years before an early stop at a planned interim analysis [2]. The composite of kidney failure, a 50% or greater fall in eGFR, or kidney or cardiovascular death occurred as 331 first events in the semaglutide group versus 410 in the placebo group (HR 0.76, 95% CI 0.66 to 0.88) [2].

The label's renal warning concerns volume depletion. Postmarketing reports include acute kidney injury, in some cases requiring hemodialysis, mostly in people who had nausea, vomiting or diarrhea, and the label says to monitor renal function in patients reporting reactions that could lead to volume depletion, especially during initiation and dose escalation [1].

## Liver disease, MASH and cirrhosis

The Ozempic label recommends no dose adjustment for [hepatic impairment](https://healthrx.com/ozempic/hepatic-impairment) [1]. That covers dosing, not outcomes in liver disease.

The liver-outcome evidence sits in MASH and at a higher dose. A phase 3 trial assigned 1,197 adults with biopsy-proven MASH and fibrosis stage F2 or F3 to [semaglutide 2.4 mg](https://healthrx.com/wegovy) weekly or placebo for a planned 240 weeks; at the week-72 interim analysis of the first 800 patients, steatohepatitis resolved without worsening fibrosis in 62.9% versus 34.3%, and fibrosis improved without worsening steatohepatitis in 36.8% versus 22.4% [3]. That dose is above Ozempic's maximum of 2 mg weekly [1], and Ozempic has no MASH or weight-loss indication [1].

Decompensated cirrhosis is a separate question, and the label's dosing statement does not address clinical outcomes in that group.

## Label guidance for transplant and HIV patients

What the label offers for transplant recipients and people living with HIV is a general caution about oral medicines rather than outcome data [1]. Ozempic delays gastric emptying and may affect the absorption of oral medicines; clinical pharmacology trials did not show an effect on absorption to a clinically relevant degree, and the label still advises caution when oral medicines are taken together [1].

Semaglutide is broken down by proteolytic cleavage of its peptide backbone and beta-oxidation of its fatty acid side chain, not by CYP enzymes, and the label describes very low potential for it to inhibit or induce CYP enzymes [1]. That does not establish whether Ozempic interacts with any particular HIV medicine. The gastric-emptying caution applies to the other oral medicines a person takes alongside it [1].

## Older age findings at a glance

The label's geriatric section reports that 744 (23.6%) of Ozempic-treated patients in the pooled glycemic-control trials were 65 or older, and that in SUSTAIN 6, 788 (48%) were 65 or older and 157 (9.6%) were 75 or older. No overall differences in safety or efficacy were detected between these patients and younger ones, but greater sensitivity of some older individuals cannot be ruled out [1].

Hypoglycemia is the interaction the label flags when Ozempic is combined with a sulfonylurea or insulin, and it says the risk may be lowered by reducing the dose of the sulfonylurea or insulin [1]. In the 30-week trial that added Ozempic to basal insulin, documented symptomatic hypoglycemia at or below 70 mg/dL occurred in 15.2% on placebo, 16.7% on 0.5 mg and 29.8% on 1 mg, with severe hypoglycemia in 0%, 0% and 1.5% [1].

## PCOS, contraception and pregnancy

Ozempic has no PCOS indication; its three indications are glycemic control, [cardiovascular risk](https://healthrx.com/ozempic/cardiovascular-impact) reduction in type 2 diabetes with established cardiovascular disease, and the kidney outcomes above [1]. The label's trials were in type 2 diabetes.

The label does not list [pregnancy](https://healthrx.com/ozempic/pregnancy-lactation) as a contraindication. The contraindications are a personal or family history of medullary thyroid carcinoma or MEN 2, and a prior serious hypersensitivity reaction to [semaglutide](https://healthrx.com/products/semaglutide) or an excipient [1]. On pregnancy it says human data are limited, that animal reproduction studies showed embryofetal mortality, structural abnormalities and growth alterations in rats at clinical exposure and early pregnancy losses or structural abnormalities in rabbits and monkeys, and that Ozempic should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus [1]. It says to discontinue Ozempic in women at least 2 months before a planned pregnancy because of the long washout period [1]. The label has no human milk data [1].

On contraception, the semaglutide labels carry no advice to switch away from an oral method, and a drug interaction study of semaglutide tablets found no clinically significant effect on ethinyl estradiol or levonorgestrel [4]. The gastric-emptying caution about other oral medicines still applies [1].

## Heart disease indication and SUSTAIN 6 results

Ozempic is indicated to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction or non-fatal stroke) in adults with type 2 diabetes and established cardiovascular disease [1]. SUSTAIN 6 randomized 3,297 adults with type 2 diabetes, 83% of whom had established cardiovascular disease, chronic kidney disease or both, to 0.5 or 1 mg weekly or placebo for 104 weeks; the composite occurred in 6.6% versus 8.9% (HR 0.74, 95% CI 0.58 to 0.95), and non-fatal stroke in 1.6% versus 2.7% (HR 0.61) [5].

Eye monitoring belongs with this. In a 2-year trial in type 2 diabetes with high cardiovascular risk, diabetic retinopathy complications occurred in 3.0% on Ozempic versus 1.8% on placebo, and in 8.2% versus 5.2% of people who had retinopathy at baseline; the label says patients with a history of diabetic retinopathy should be monitored for progression [1].

## Warnings to watch across special populations

- Acute pancreatitis: persistent severe abdominal pain, sometimes radiating to the back, with or without vomiting; the label says to discontinue Ozempic if pancreatitis is suspected [1].
- Severe gastrointestinal reactions: Ozempic is not recommended in patients with severe gastroparesis [1].
- Hypersensitivity: anaphylaxis and angioedema have been reported, and the label says to discontinue and treat promptly [1].
- Gallbladder disease: gallbladder studies are indicated if cholelithiasis or cholecystitis is suspected [1].
- Pulmonary aspiration during general anesthesia or deep sedation: the label instructs patients to tell healthcare providers about planned surgery or procedures [1].

Check what you know

Think you have it? Try 4 quick questions and see what the article says.

1. In the FLOW trial, how many first kidney or cardiovascular events occurred in the semaglutide group?

Question 1 of 4

Score: 0 right, 0 of 4 answered

Printable medication review sheet

Ozempic special populations medication review sheet

Use this sheet before a visit to discuss Ozempic with your prescriber or pharmacist if you have kidney, liver, transplant, HIV, older age, pregnancy plans or other medicine questions covered in this article.

[Open the fill-in sheet](https://healthrx.com/printables/ozempic/special-populations) Fill it in, print it or save it as a PDF. No sign-up.

Questions worth asking

Choose the questions you want to keep Do I need my kidney function checked if I have nausea or vomiting on Ozempic? Can Ozempic cause kidney injury if I become dehydrated? Does my kidney disease change how I should start and raise my Ozempic dose? Which other medicines I take could raise my risk of kidney problems with Ozempic? What kidney tests should I ask for if my kidney function drops while on Ozempic?

Frequently asked questions

Does Ozempic need a dose adjustment in kidney disease?

No. The label recommends no dose adjustment for renal impairment and reports no clinically relevant change in semaglutide exposure in people with renal impairment, including kidney failure [1]. It also carries a kidney indication; in FLOW, there were 331 first kidney or cardiovascular events on semaglutide 1 mg weekly versus 410 on placebo (HR 0.76) [2]. The label's renal warning is acute kidney injury from volume depletion, and it says to monitor renal function in people reporting reactions that could lead to it [1].

Can transplant recipients take Ozempic?

The label addresses this only indirectly: Ozempic delays gastric emptying and may affect absorption of oral medicines, clinical pharmacology trials did not show a clinically relevant effect on absorption, and caution is advised when oral medicines are taken together [1].

Is Ozempic safe for people with HIV?

Semaglutide is broken down by proteolytic cleavage and beta-oxidation rather than by CYP enzymes, and the label describes very low potential to inhibit or induce CYP enzymes [1]. That does not establish whether Ozempic interacts with a particular HIV medicine. The label caution about delayed gastric emptying and other oral medicines applies [1].

Can Ozempic be used in liver disease or cirrhosis?

No dose adjustment is recommended for hepatic impairment [1]. The MASH trial that showed histologic benefit used 2.4 mg weekly in adults with fibrosis stage F2 or F3, and that dose is above Ozempic's 2 mg maximum [3][1]. The label's dosing statement does not address clinical outcomes in decompensated cirrhosis.

Do older adults tolerate Ozempic differently?

In the label's pooled glycemic-control trials, 744 (23.6%) of Ozempic-treated patients were 65 or older, and in SUSTAIN 6, 48% were 65 or older and 9.6% were 75 or older; no overall differences in safety or efficacy were detected, though greater sensitivity in some older people cannot be ruled out [1]. Hypoglycemia risk rises when Ozempic is combined with a sulfonylurea or insulin, and the label says reducing that dose may lower the risk [1].

Does Ozempic affect birth control pills?

A drug interaction study of semaglutide tablets found no clinically significant effect on ethinyl estradiol or levonorgestrel, and the semaglutide labels carry no advice to switch contraceptive methods [4]. The label does say to discontinue Ozempic at least 2 months before a planned pregnancy because of the long washout period [1].

References

Show all 5 references Hide references

1. U.S. National Library of Medicine, DailyMed. Ozempic injection (Novo Nordisk) prescribing information. [Ozempic injection (Novo Nordisk) label](https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=adec4fd2-6858-4c99-91d4-531f5f2a2d79)
2. Perkovic V, Tuttle KR, Rossing P, Mahaffey KW, Mann JFE, Bakris G, et al. [Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes](https://pubmed.ncbi.nlm.nih.gov/38785209/). N Engl J Med. 2024;391(2):109-121.
3. Sanyal AJ, Newsome PN, Kliers I, Østergaard LH, Long MT, Kjær MS, et al. [Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis](https://pubmed.ncbi.nlm.nih.gov/40305708/). N Engl J Med. 2025;392(21):2089-2099.
4. U.S. National Library of Medicine, DailyMed. [Rybelsus](https://healthrx.com/glp-1/rybelsus) and Ozempic tablets (Novo Nordisk) ([oral semaglutide](https://healthrx.com/rybelsus)) prescribing information. [Rybelsus and Ozempic tablets (Novo Nordisk) (oral semaglutide) label](https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=27f15fac-7d98-4114-a2ec-92494a91da98)
5. Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, et al. [Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes](https://pubmed.ncbi.nlm.nih.gov/27633186/). N Engl J Med. 2016;375(19):1834-1844.

Next in this cluster

Related reading

- [semaglutide 0 5 Ozempic pharmacokinetics](https://healthrx.com/ozempic/pharmacokinetics)
- [finasteride Finasteride in Special Populations](https://healthrx.com/finasteride/special-populations)
- [semaglutide 0 5 Can you take Ozempic with gabapentin](https://healthrx.com/interactions-ozempic/with-gabapentin)
- [semaglutide 0 5 Ozempic and prednisone interaction](https://healthrx.com/interactions-ozempic/with-prednisone)
- [semaglutide 0 5 Ozempic storage](https://healthrx.com/ozempic/storage-stability)
- [semaglutide 0 5 Ozempic switching](https://healthrx.com/ozempic/switching-protocols)
- [semaglutide 0 5 Ozempic travel protocol](https://healthrx.com/ozempic/travel-protocols)
- [semaglutide 0 5 Does TRICARE cover Ozempic](https://healthrx.com/ozempic/tricare-coverage)
- [semaglutide 0 5 Does UnitedHealthcare cover Ozempic](https://healthrx.com/ozempic/unitedhealthcare-coverage)
- [semaglutide 0 5 Ozempic young adult dosing](https://healthrx.com/ozempic/young-adult-dosing)
- [semaglutide 0 5 Ozempic lab schedule young adults](https://healthrx.com/ozempic/young-adult-monitoring)
- [semaglutide 0 5 Ozempic side effects young adults](https://healthrx.com/ozempic/young-adult-safety)
- [semaglutide 0 5 Ozempic and acetaminophen interaction](https://healthrx.com/interactions-ozempic/with-acetaminophen)
- [wegovy vs ozempic Wegovy vs Ozempic](https://healthrx.com/compare-glp-1/wegovy-vs-ozempic--efficacy)

![ozempic special populations: diverse adult patients waiting in outpatient clinic area](https://zwulxpn434zaufgz.public.blob.vercel-storage.com/page-images/ozempic/special-populations.webp)

Patients with kidney, liver or transplant history, or HIV, often need tailored review before starting or continuing treatment. Full ozempic special populations guide and sources at [healthrx.com/ozempic](https://healthrx.com/ozempic).
